Across TCGA pan-cancer cohorts, LYPD2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LYPD2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LYPD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYPD2 expression acts as an unfavorable survival marker.

SKCM are the cancer types where LYPD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.506	0.783	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LYPD2 tumor-vs-normal RNA expression · all LYPD2 data types